Eisai R&d Management Co., Ltd.

Tomoko Sekiya

Hirokazu Tanaka

Norimasa Miyamoto

Naoko Massaki

Takayuki Hida

Kokichi Harada

Michiko Kosasa

Eiki Takahashi

Toru Sawai

Kenichi Morita

Takashi Seiki

Tohru Arai

The present invention provides a screening method for determining whether a substance of interest is a substance which alters GPR120 mediated cell stimulating activities, comprising using a substance of interest, a biomembrane containing GPR120, or cells containing said biomembrane, and phospholipase or salts thereof. According to a screening method of the present invention, the method can screen substances such as CCK and GLP-1 which are involved in the secretion of hormones in gastrointestinal tracts.

Method for screening of substance which alter GPR120-mediated cell-stimulating activities

The present invention relates to a screening method for determining whether a substance of interest is a substance which alters GPR40-mediated cell stimulating activities, comprising using a substance of interest, a biomembrane containing GPR40, or cells containing said biomembrane, and phospholipase or salts thereof. According to the present invention, substances involved in insulin secretion can be screened. In addition, according to the present invention, substance useful for the prevention or treatment of diabetes, diabetic complications and degenerative diseases, hyperglycemia, polyuria, ketonemia, acidosis, insulin resistance, impaired glucose tolerance, neurodegenerative diseases, insulinoma, cancers, hyperinsulinemia, hyperglyceridemia, fatty liver, hypoglycemia due to insulin hypersecretion, arteriosclerosis, hyperlipidemia, cerebral stroke, obesity, various diseases induced by diabetes or obesity, and the like.

Method of screening substance useful in treating disease with the use of GPR40 and phospholipase

Relaxin-3 is found to have feeding-stimulating activity, body weight increasing activity, and fat weight increasing activity when intracerebroventricularly administered to rats through observation of amount of feeding, body weight and fat weight after administration of relaxin-3. This invention includes: a polypeptide having useful effects in stimulating feeding, increasing body weight, and fattening; a therapeutic agent containing the polypeptide; a method of screening for a compound, a substance, or a salt thereof which activates or suppresses a receptor of the polypeptide; a kit for screening; and an agent with a substance which inhibits expression of the polypeptide, such as a feeding-suppressing agent, a therapeutic agent for the treatment of obesity, and a therapeutic agent for the treatment of diabetes.

Methods of affecting feeding and weight in mammals by administration of relaxin-3

Growing community of inventors

Tsukuba, Japan

Tomoko Sekiya